|
CN105246882A
(zh)
*
|
2013-01-16 |
2016-01-13 |
密执安大学评议会 |
BCL-2/Bcl-xL抑制剂和使用所述抑制剂的治疗方法
|
|
CA2939121C
(en)
|
2014-01-28 |
2020-11-24 |
Mayo Foundation For Medical Education And Research |
Effective treatment of osteoarthritis, pulmonary disease, ophthalmic disease, and atherosclerosis by removing senescent cells at the site of the disease
|
|
EP3139942B1
(en)
|
2014-05-05 |
2019-12-18 |
Bioventures, Llc |
COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
|
|
AU2015292710A1
(en)
|
2014-07-22 |
2017-02-16 |
Bioventures, Llc. |
Compositions and methods for selectively depleting senescent cells
|
|
US20180000816A1
(en)
*
|
2015-02-06 |
2018-01-04 |
Unity Biotechnology, Inc. |
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
|
|
CA2981753A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Unity Biotechnology, Inc. |
Compounds and uses in treatment of senescence-associated conditions
|
|
US11111259B2
(en)
|
2015-12-18 |
2021-09-07 |
Unity Biotechnology, Inc. |
Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
|
|
WO2017172826A1
(en)
|
2016-03-28 |
2017-10-05 |
Presage Biosciences, Inc. |
Pharmaceutical combinations for the treatment of cancer
|
|
KR102447884B1
(ko)
*
|
2016-04-21 |
2022-09-27 |
바이오벤처스, 엘엘씨 |
항-세포자멸적 bcl-2 계열 단백질의 열화를 유도하는 화합물 및 이의 용도
|
|
CN106177955B
(zh)
*
|
2016-08-18 |
2018-03-16 |
广州威溶特医药科技有限公司 |
Bcl‑xL抑制剂和溶瘤病毒在制备抗肿瘤药物中的应用
|
|
WO2018098534A1
(en)
*
|
2016-12-02 |
2018-06-07 |
Garvan Institute Of Medical Research |
Methods of treating cancer and reagents thereof
|
|
US20200354336A9
(en)
*
|
2017-08-11 |
2020-11-12 |
Unity Biotechnology, Inc. |
Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
|
|
WO2019033122A1
(en)
*
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|
|
AU2018314280B2
(en)
*
|
2017-08-11 |
2023-07-20 |
Rsem, Société En Commandite |
Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells
|
|
US10588916B2
(en)
|
2017-10-31 |
2020-03-17 |
Unity Biotechnology, Inc. |
Technology to inhibit vascular changes that lead to vision loss in the eye
|
|
WO2019133988A1
(en)
|
2017-12-30 |
2019-07-04 |
Unity Biotechnology, Inc. |
Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
|
|
AU2019207616A1
(en)
|
2018-01-10 |
2020-07-09 |
Recurium Ip Holdings, Llc |
Benzamide compounds
|
|
JP7385284B2
(ja)
*
|
2018-01-22 |
2023-11-22 |
バイオベンチャーズ・リミテッド・ライアビリティ・カンパニー |
癌処置のためのｂｃｌ－２タンパク質分解剤
|
|
SI3788042T1
(sl)
|
2018-04-29 |
2025-06-30 |
Beigene Switzerland Gmbh |
Zaviralci BCL-2
|
|
US10738042B2
(en)
|
2018-04-30 |
2020-08-11 |
Unity Biotechnology, Inc. |
Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
CN117866015A
(zh)
|
2018-04-30 |
2024-04-12 |
联合生物科技公司 |
一种临床管理中使用的化合物及其用途
|
|
CA3056878C
(en)
|
2018-04-30 |
2021-03-30 |
Unity Biotechnology |
Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
WO2019221755A1
(en)
|
2018-05-18 |
2019-11-21 |
Bioventures, Llc |
Piperlongumine analogues and uses thereof
|
|
US10717722B2
(en)
|
2018-06-13 |
2020-07-21 |
Unity Biotechnology, Inc. |
Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
|
|
US11491168B2
(en)
|
2018-07-31 |
2022-11-08 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
|
|
AU2019315466B2
(en)
|
2018-07-31 |
2022-05-19 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Synergistic antitumor effect of Bcl-2 inhibitor combined with rituximab and/or bendamustine or Bcl-2 inhibitor combined with CHOP
|
|
EP3672594B1
(en)
|
2018-07-31 |
2021-09-29 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
|
|
TW202019421A
(zh)
*
|
2018-07-31 |
2020-06-01 |
大陸商蘇州亞盛藥業有限公司 |
Bcl-2/Bcl-xL抑制劑與化療藥物的組合及其應用
|
|
TWI725488B
(zh)
|
2018-07-31 |
2021-04-21 |
大陸商蘇州亞盛藥業有限公司 |
Bcl-2抑制劑與化療藥的組合產品及其在預防及/或治療疾病中的用途
|
|
CN114522167A
(zh)
*
|
2018-07-31 |
2022-05-24 |
苏州亚盛药业有限公司 |
Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
|
|
WO2020041405A1
(en)
|
2018-08-22 |
2020-02-27 |
Newave Pharmaceutical Inc. |
Bcl-2 inhibitors
|
|
US11872237B2
(en)
|
2018-12-28 |
2024-01-16 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Pharmaceutical composition and preparation method thereof
|
|
TWI729662B
(zh)
*
|
2019-01-04 |
2021-06-01 |
大陸商蘇州亞盛藥業有限公司 |
一種磺胺類化合物及製備磺胺類化合物的製程
|
|
EP3906235B1
(en)
*
|
2019-01-04 |
2023-03-15 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Method for preparing sulfonamides drugs
|
|
TWI770503B
(zh)
*
|
2019-05-13 |
2022-07-11 |
大陸商蘇州亞盛藥業有限公司 |
用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
|
|
TW202114692A
(zh)
*
|
2019-07-02 |
2021-04-16 |
大陸商蘇州亞盛藥業有限公司 |
一種含有mTOR抑制劑的藥物組合及其應用
|
|
WO2021018240A1
(en)
*
|
2019-07-31 |
2021-02-04 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combination product of a bcl-2/bcl-xl inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
|
|
WO2021066873A1
(en)
|
2019-10-03 |
2021-04-08 |
Newave Pharmaceutical Inc. |
Condensed heterocycles as bcl-2 inhibitors
|
|
WO2021078301A1
(zh)
*
|
2019-10-24 |
2021-04-29 |
上海科技大学 |
蛋白降解剂及其在疾病治疗中的应用
|
|
TWI885019B
(zh)
*
|
2019-11-27 |
2025-06-01 |
大陸商蘇州亞盛藥業有限公司 |
用於預測靶向細胞凋亡途徑的化合物的抗癌功效的方法和組合物
|
|
EP4069233A4
(en)
*
|
2019-12-04 |
2024-03-13 |
Ascentage Pharma (Suzhou) Co., Ltd. |
PHARMACEUTICAL COMBINATION AND USE THEREOF
|
|
US20230025865A1
(en)
*
|
2019-12-11 |
2023-01-26 |
The Regents Of The University Of Michigan |
COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF Bcl-2 AND Bcl-xL ANTAGONISTS
|
|
CN113350281B
(zh)
*
|
2020-03-02 |
2023-08-15 |
苏州亚盛药业有限公司 |
载药聚合物胶束及其制剂和制备方法
|
|
US20220296557A1
(en)
*
|
2020-04-10 |
2022-09-22 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Combinations of bcl-2/bcl-xl inhibitors and related uses
|
|
WO2021208963A1
(en)
|
2020-04-15 |
2021-10-21 |
Beigene, Ltd. |
Bcl-2 inhibitor
|
|
WO2021233948A1
(en)
|
2020-05-19 |
2021-11-25 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Method to treat a pathogen lung infection
|
|
EP4175644A1
(en)
|
2020-07-06 |
2023-05-10 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination of antineoplastic antibiotics and bcl-2 inhibitors for the treatment of npm-1-driven acute myeloid leukemia (aml)
|
|
WO2022012481A1
(en)
*
|
2020-07-13 |
2022-01-20 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Crystalline or Amorphous form of Bcl-2/Bcl-xL inhibitor compound or its salts
|
|
CN114053288B
(zh)
*
|
2020-07-31 |
2024-11-19 |
苏州亚盛药业有限公司 |
肺部疾病治疗的组合物和方法
|
|
JP7688141B2
(ja)
*
|
2020-11-10 |
2025-06-03 |
ユニティ バイオテクノロジー インコーポレイテッド |
Ｂｃｌの結晶性固体メグルミン塩阻害物質、並びに前記阻害物質を作製及び使用する方法
|
|
WO2022111647A1
(en)
*
|
2020-11-27 |
2022-06-02 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Formulation combination containing freeze-dried formulation and reconstituted solvent, preparation method and application thereof
|
|
US12454674B2
(en)
|
2020-12-04 |
2025-10-28 |
University Of Notre Dame Du Lac |
Method of encapsulating single cells utilizing an alternating current electrospray
|
|
US20250099440A1
(en)
*
|
2021-08-02 |
2025-03-27 |
Ascentage Pharma (Suzhou) Co., Ltd. |
A pharmaceutical combination and use thereof
|
|
EP4565236A1
(en)
*
|
2022-08-02 |
2025-06-11 |
Beijing Neox Biotech Limited |
Bcl-xl degrading compounds
|
|
WO2024051741A1
(zh)
*
|
2022-09-06 |
2024-03-14 |
西藏海思科制药有限公司 |
一种抑制Bcl-2或Bcl-xL的化合物及其在医药上的应用
|
|
WO2024245312A1
(en)
*
|
2023-05-30 |
2024-12-05 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Bcl-2/bcl-xl protein degrader and use thereof
|
|
WO2025087879A2
(en)
|
2023-10-23 |
2025-05-01 |
Institut National de la Santé et de la Recherche Médicale |
Suppressing the pi3kgamma/akt signalling pathway for the treatment of acute myeloid leukemia
|